Clients & Cases

June 9, 2017

PTAB Rules in Favor of Fish Client Coherus, Invalidates Competitor’s Humira® Patents

On June 9, 2017, the Patent Trial and Appeal Board (PTAB) ruled in favor of Fish client Coherus BioScience’s petitions for Inter Partes Review (IPR) of AbbVie’s U.S. Patent 9,073,987 (‘987 Patent) and U.S. Patent 9,017,680 (‘680 Patent). The PTAB’s decision invalidates all claims of the patents that were directed to a method of treating rheumatoid arthritis.  In May of 2017, Coherus prevailed at the PTAB in a similar IPR proceeding involving AbbVie’s U.S. Patent 8,889,135 (‘135 Patent).

These decisions are the first to invalidate core AbbVie patents covering the blockbuster drug Humira® in the United States. To read the press release on the ‘135 Patent decisions, click here.

No Comments

Sorry, the comment form is closed at this time.

Fill out the form below to receive our monthly newsletter and updates on your selected areas of interest. You can unsubscribe at any time by clicking the unsubscribe link at the bottom of the email.

  • Fish & Richardson P.C. is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the services you requested from us. From time to time, we would like to contact you about our services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.
  • In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.
  • You can unsubscribe from these communications at any time. This can be done by clicking the unsubscribe link at the bottom of marketing emails you receive from us, or by emailing info@fr.com stating that you would like to be unsubscribed.
  • This field is for validation purposes and should be left unchanged.